Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
Psychedelic Alpha’s Josh Hardman speaks with newly appointed Helus Pharma CEO Michael Cola in a brief Q&A on execution, regulatory rigor, and scaling serotonergic CNS medicines.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. In this Issue, we take a deep dive into psychedelic dosing and ceremony through interviews, research reviews, and practitioner perspectives.
Trump Administration Vetoed Compass Pathways Priority Voucher • Ibogaine in Focus (State Bills Progress, Safety and Regulation, State Programs and Global Supply, Drug Development Remains Early-Stage, DemeRx Shares Phase 1 Data • Definium Therapeutics Sued by Former Vendor Over Alleged Trade Secret Theft • Psychedelics Surface in Newly Released Epstein Documents • Fresh State Bills Add to Growing Psychedelics Docket • and more…
Psychedelic Alpha’s Charles Bliss speaks with astrobiologist Dr. Bruce Damer about the Center for MINDS’ mission and how it is picking up the “abandoned thread” of research into psychedelics as catalysers of creativity and innovation.
Oregon Psilocybin Services (OPS) has now published its third dataset for 2025, with updates summarised in our Oregon Psilocybin Services Tracker. Here, we share a summary of the main takeaways for Pα+ subscribers.
A state-by-state and federal review of psychedelics-related bills introduced or advanced in January 2026, including pilot programs, trigger laws, and research programs.
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. In this Issue, we take a deep dive into psychedelic dosing and ceremony through interviews, research reviews, and practitioner perspectives.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. In this Issue, we take a deep dive into the science and practice of psychedelic preparation through interviews, research reviews, and practitioner perspectives.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
Archived versions of our Psychedelic News Feed.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing January 26, 2026.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing January 19, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing January 12, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing January 05, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing December 15, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing December 8, 2025.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).
Insights and interviews delivered to your inbox. No spam, just valuable information.
